S&P 500   4,270.13 (-0.32%)
DOW   33,678.00 (+0.31%)
QQQ   349.63 (-1.47%)
AAPL   178.33 (-0.49%)
MSFT   323.96 (-2.91%)
META   265.83 (-1.95%)
GOOGL   122.74 (-3.59%)
AMZN   121.50 (-4.04%)
TSLA   225.49 (+1.89%)
NVDA   377.09 (-2.44%)
NIO   7.83 (-0.63%)
BABA   85.46 (-1.43%)
AMD   118.40 (-4.69%)
T   16.03 (+2.30%)
F   13.53 (+4.64%)
MU   67.24 (-0.44%)
CGC   0.73 (-1.74%)
GE   105.96 (+0.47%)
DIS   92.52 (+0.39%)
AMC   4.74 (+2.16%)
PFE   38.91 (+1.41%)
PYPL   64.21 (-1.25%)
NFLX   401.37 (+0.52%)
S&P 500   4,270.13 (-0.32%)
DOW   33,678.00 (+0.31%)
QQQ   349.63 (-1.47%)
AAPL   178.33 (-0.49%)
MSFT   323.96 (-2.91%)
META   265.83 (-1.95%)
GOOGL   122.74 (-3.59%)
AMZN   121.50 (-4.04%)
TSLA   225.49 (+1.89%)
NVDA   377.09 (-2.44%)
NIO   7.83 (-0.63%)
BABA   85.46 (-1.43%)
AMD   118.40 (-4.69%)
T   16.03 (+2.30%)
F   13.53 (+4.64%)
MU   67.24 (-0.44%)
CGC   0.73 (-1.74%)
GE   105.96 (+0.47%)
DIS   92.52 (+0.39%)
AMC   4.74 (+2.16%)
PFE   38.91 (+1.41%)
PYPL   64.21 (-1.25%)
NFLX   401.37 (+0.52%)
S&P 500   4,270.13 (-0.32%)
DOW   33,678.00 (+0.31%)
QQQ   349.63 (-1.47%)
AAPL   178.33 (-0.49%)
MSFT   323.96 (-2.91%)
META   265.83 (-1.95%)
GOOGL   122.74 (-3.59%)
AMZN   121.50 (-4.04%)
TSLA   225.49 (+1.89%)
NVDA   377.09 (-2.44%)
NIO   7.83 (-0.63%)
BABA   85.46 (-1.43%)
AMD   118.40 (-4.69%)
T   16.03 (+2.30%)
F   13.53 (+4.64%)
MU   67.24 (-0.44%)
CGC   0.73 (-1.74%)
GE   105.96 (+0.47%)
DIS   92.52 (+0.39%)
AMC   4.74 (+2.16%)
PFE   38.91 (+1.41%)
PYPL   64.21 (-1.25%)
NFLX   401.37 (+0.52%)
S&P 500   4,270.13 (-0.32%)
DOW   33,678.00 (+0.31%)
QQQ   349.63 (-1.47%)
AAPL   178.33 (-0.49%)
MSFT   323.96 (-2.91%)
META   265.83 (-1.95%)
GOOGL   122.74 (-3.59%)
AMZN   121.50 (-4.04%)
TSLA   225.49 (+1.89%)
NVDA   377.09 (-2.44%)
NIO   7.83 (-0.63%)
BABA   85.46 (-1.43%)
AMD   118.40 (-4.69%)
T   16.03 (+2.30%)
F   13.53 (+4.64%)
MU   67.24 (-0.44%)
CGC   0.73 (-1.74%)
GE   105.96 (+0.47%)
DIS   92.52 (+0.39%)
AMC   4.74 (+2.16%)
PFE   38.91 (+1.41%)
PYPL   64.21 (-1.25%)
NFLX   401.37 (+0.52%)
NYSE:ABBV

AbbVie (ABBV) Stock Forecast, Price & News

$136.48
+1.05 (+0.78%)
(As of 03:21 PM ET)
Compare
Today's Range
$134.26
▼
$137.06
50-Day Range
$133.47
▼
$164.90
52-Week Range
$131.10
▼
$168.11
Volume
2.32 million shs
Average Volume
5.95 million shs
Market Capitalization
$240.79 billion
P/E Ratio
32.26
Dividend Yield
4.34%
Price Target
$163.40
ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

AbbVie MarketRank™ Forecast

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
19.5% Upside
$163.40 Price Target
Short Interest
Healthy
0.68% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.34
Upright™ Environmental Score
News Sentiment
0.18mentions of AbbVie in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$13.28 M Sold Last Quarter
Proj. Earnings Growth
0.64%
From $10.97 to $11.04 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.77 out of 5 stars

Medical Sector

49th out of 982 stocks

Pharmaceutical Preparations Industry

17th out of 481 stocks

See Top Rated MarketRank™ Stocks Here

ABBV stock logo

About AbbVie (NYSE:ABBV) Stock

AbbVie Inc. is a US-based biopharma company with global operations. The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. AbbVie, like its parent Abbot Laboratories, is a well-established dividend growth stock.

Over the years, AbbView Inc. has made numerous acquisitions. Among the more notable are ImmuVen, Pharamcyclics and Allergan plc. Allergan plc was an Ireland-based pharmaceutical company focused on health-oriented aesthetic products and is the owner of Botox. Botox accounts for the bulk of the company’s Aesthetics portfolio revenue and about 4% of the net as of 2022. The total revenue in 2021 was $56.20 billion with a 31% operating margin.

Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community.

The company’s original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions.

The company is focused on research and has a number of collaborations and partnerships to that end. Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. Assuming there are 2 highly effective drugs for 1 disease, PMedicine seeks to identify which patients respond better to each.

As of 2022, AbbVie employed more than 50,000 people globally with 21,000 in STEM-related positions. To date, the company had invested more than $50 billion into research through more than 250 partnerships. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. The company’s operations span 20 countries, treating more than 60 million people and 40 conditions annually.

AbbVie has 5 focus areas for its research and products. These are Immunology, Oncology, Neurology, Virology and Eye Care. The company has a robust pipeline of new products that are in some stage of clinical trials. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions.

AbbVie is a leader in ESG and sustainability. The company is a member of the Fortune 100 and one of the Fortune 100’s “Best Companies To Work For”. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most.

Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

ABBV Stock News Headlines

June 1, 2023 | marketbeat.com
20 Best Healthcare Dividend Stocks to Invest in (ABBV)
Healthcare, like many other sectors, produces dividends. Learn more about how to invest in healthcare trends and earn dividends along the way with MarketBeat.
May 31, 2023 | marketbeat.com
The How and Why of Investing in Biotech Stocks (ABBV)
One fascinating sector to invest in is the biotech sector which includes companies involved in the research and development of therapeutics and vaccines
June 7, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
June 7, 2023 | finance.yahoo.com
AbbVie Announces Reimbursement for VRAYLAR® (cariprazine) for the Treatment of Schizophrenia under the Non-Insured Health Benefits (NIHB) Program
June 7, 2023 | finance.yahoo.com
Should You Invest in AbbVie (ABBV)?
June 6, 2023 | finance.yahoo.com
AbbVie to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 6, 2023 | msn.com
IBM, CVX, or ABBV: Which Dividend Aristocrat Stock is the Most Compelling Pick?
June 5, 2023 | seekingalpha.com
AbbVie Stock May Be Falling On Humira LOE - But Investors Shouldn't Panic
June 7, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
June 5, 2023 | markets.businessinsider.com
Barclays Sticks to Its Hold Rating for AbbVie (ABBV)
June 4, 2023 | finance.yahoo.com
AbbVie (NYSE:ABBV) shareholders have earned a 18% CAGR over the last three years
June 2, 2023 | finance.yahoo.com
AbbVie Inc.: Despite Humira Biosimilar Headwinds, AbbVie's Strong Portfolio Should Support Steady Earnings
June 1, 2023 | benzinga.com
Amgen shares are trading lower as Coherus BioSciences plans to sell a competing biosimilar of AbbVie's Humira at a discount.
June 1, 2023 | benzinga.com
AbbVie shares are trading lower as Coherus BioSciences plans to sell a biosimilar of the company's Humira at a discount.
June 1, 2023 | markets.businessinsider.com
Why Is AbbVie Stock Trading Down Today?
June 1, 2023 | finance.yahoo.com
Why AbbVie and Amgen Are Moving Lower Today
June 1, 2023 | finance.yahoo.com
UPDATE 1-AstraZeneca to stop developing Crohn's disease drug
May 31, 2023 | markets.businessinsider.com
AbbVie Says Upadacitinib 30 Mg Meets Primary Goals In SLE Patients In Mid-stage Study
May 31, 2023 | msn.com
AbbVie meets key goals for Rinvoq in mid-stage SLE trial
May 31, 2023 | finance.yahoo.com
Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus
May 28, 2023 | americanbankingnews.com
Brokers Offer Predictions for AbbVie Inc.'s Q1 2024 Earnings (NYSE:ABBV)
May 26, 2023 | finance.yahoo.com
Is AbbVie Inc.'s (NYSE:ABBV) ROE Of 57% Impressive?
May 26, 2023 | forbes.com
Should You Pick AbbVie Stock Over LLY?
May 26, 2023 | americanbankingnews.com
Brokerages Set AbbVie Inc. (NYSE:ABBV) PT at $164.00
May 25, 2023 | finance.yahoo.com
2 Dividend Kings on Sale That Are Yielding More Than 4%
May 24, 2023 | finance.yahoo.com
Top Research Reports for AbbVie, Intel & Qualcomm
May 24, 2023 | finance.yahoo.com
Modak Congratulates AbbVie on Winning the Bio-IT World Innovative Practices Award 2023
See More Headlines

ABBV Price History

ABBV Company Calendar

Ex-Dividend for 5/15 Dividend
4/13/2023
Last Earnings
4/27/2023
Dividend Payable
5/15/2023
Today
6/07/2023
Next Earnings (Estimated)
8/04/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Drug Manufacturers—General
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NYSE:ABBV
CUSIP
00287Y10
CIK
1551152
Web
www.abbvie.com
Phone
(847) 932-7900
Fax
302-655-5049
Employees
50,000
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$163.40
High Stock Price Forecast
$195.00
Low Stock Price Forecast
$140.00
Forecasted Upside/Downside
+20.7%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
14 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$4.23
Trailing P/E Ratio
32.01
Forward P/E Ratio
12.34
P/E Growth
2.49
Net Income
$11.84 billion
Net Margins
13.37%
Pretax Margin
15.90%
Return on Equity
153.92%
Return on Assets
16.91%

Debt

Debt-to-Equity Ratio
4.46
Current Ratio
0.96
Quick Ratio
0.82

Sales & Book Value

Annual Sales
$58.05 billion
Price / Sales
4.12
Cash Flow
$18.50 per share
Price / Cash Flow
7.32
Book Value
$9.78 per share
Price / Book
13.85

Miscellaneous

Outstanding Shares
1,764,290,000
Free Float
1,759,703,000
Market Cap
$238.90 billion
Optionable
Optionable
Beta
0.58

Social Links


Key Executives

  • Mr. Richard A. GonzalezMr. Richard A. Gonzalez (Age 69)
    Chairman & CEO
    Comp: $6.95M
  • Mr. Robert A. MichaelMr. Robert A. Michael (Age 53)
    Vice Chairman & Pres
    Comp: $4M
  • Mr. Scott T. ReentsMr. Scott T. Reents (Age 55)
    Exec. VP & CFO
    Comp: $2.97M
  • Dr. Azita Saleki-Gerhardt Ph.D.Dr. Azita Saleki-Gerhardt Ph.D. (Age 60)
    Exec. VP of Operations
    Comp: $2.58M
  • Mr. Jeffrey Ryan StewartMr. Jeffrey Ryan Stewart (Age 54)
    Exec. VP & Chief Commercial Officer
    Comp: $2.98M
  • Dr. Nicholas R. Donoghoe M.D. (Age 42)
    Sr. VP of R&D and COO
  • Dr. Thomas J. Hudson M.D. (Age 61)
    Sr. VP of R&D and Chief Scientific Officer
  • Ms. Elizabeth Shea
    VP of Investor Relations
  • Ms. Tracie Haas
    Sr. VP of Corp. Responsibility, Brand & Communications
  • Mr. Timothy J. RichmondMr. Timothy J. Richmond (Age 57)
    Exec. VP & Chief HR Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ABBV Stock - Frequently Asked Questions

Should I buy or sell AbbVie stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 8 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ABBV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABBV, but not buy additional shares or sell existing shares.
View ABBV analyst ratings or view top-rated stocks.

What is AbbVie's stock price forecast for 2023?

14 equities research analysts have issued 1 year price objectives for AbbVie's shares. Their ABBV share price forecasts range from $140.00 to $195.00. On average, they predict the company's stock price to reach $163.40 in the next twelve months. This suggests a possible upside of 20.7% from the stock's current price.
View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts.

How have ABBV shares performed in 2023?

AbbVie's stock was trading at $161.61 on January 1st, 2023. Since then, ABBV stock has decreased by 16.2% and is now trading at $135.41.
View the best growth stocks for 2023 here.

Are investors shorting AbbVie?

AbbVie saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 11,970,000 shares, a decline of 23.5% from the April 30th total of 15,650,000 shares. Based on an average daily trading volume, of 5,780,000 shares, the short-interest ratio is currently 2.1 days. Approximately 0.7% of the company's stock are sold short.
View AbbVie's Short Interest.

When is AbbVie's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our ABBV earnings forecast.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) issued its quarterly earnings results on Thursday, April, 27th. The company reported $2.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.44 by $0.02. The firm earned $12.23 billion during the quarter, compared to analyst estimates of $12.23 billion. AbbVie had a trailing twelve-month return on equity of 153.92% and a net margin of 13.37%. AbbVie's revenue for the quarter was down 9.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.16 earnings per share.
Read the conference call transcript.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Thursday, February 16th. Investors of record on Friday, April 14th will be given a dividend of $1.48 per share on Monday, May 15th. This represents a $5.92 annualized dividend and a dividend yield of 4.37%. The ex-dividend date of this dividend is Thursday, April 13th.
Read our dividend analysis for ABBV.

What ETFs hold AbbVie's stock?

ETFs with the largest weight of AbbVie (NYSE:ABBV) stock in their portfolio include First Trust Morningstar Dividend Leaders Index (FDL), First Trust Nasdaq Pharmaceuticals ETF (FTXH), Horizon Kinetics Medical ETF (MEDX), iShares Core High Dividend ETF (HDV), Invesco Dynamic Pharmaceuticals ETF (PJP), VanEck Pharmaceutical ETF (PPH), Sound Equity Income ETF (SDEI) and iShares U.S. Healthcare ETF (IYH).

Is AbbVie a good dividend stock?

AbbVie (NYSE:ABBV) pays an annual dividend of $5.92 per share and currently has a dividend yield of 4.33%. ABBV has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 51 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 139.95%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 53.62% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ABBV.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its second quarter 2023 earnings guidance on Friday, April, 28th. The company provided earnings per share (EPS) guidance of $2.90-$3.00 for the period, compared to the consensus earnings per share estimate of $2.85. The company issued revenue guidance of $13.50 billion-$13.50 billion, compared to the consensus revenue estimate of $13.36 billion.

What is Richard A. Gonzalez's approval rating as AbbVie's CEO?

580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among the company's employees.

What other stocks do shareholders of AbbVie own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Rogers Communications (RCI) and Open Text (OTEX).

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.86%), State Street Corp (4.37%), Geode Capital Management LLC (1.93%), Charles Schwab Investment Management Inc. (1.22%), Bank of New York Mellon Corp (1.14%) and Price T Rowe Associates Inc. MD (1.00%). Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents and Timothy J Richmond.
View institutional ownership trends.

How do I buy shares of AbbVie?

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $135.41.

How much money does AbbVie make?

AbbVie (NYSE:ABBV) has a market capitalization of $238.90 billion and generates $58.05 billion in revenue each year. The company earns $11.84 billion in net income (profit) each year or $4.23 on an earnings per share basis.

How many employees does AbbVie have?

The company employs 50,000 workers across the globe.

Does AbbVie have any subsidiaries?
The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC.
Read More
How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The official website for the company is www.abbvie.com. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049.

This page (NYSE:ABBV) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -